Usa state New Jersey hospital covid-19 pandemic patient Usa state New Jersey

How to launch a drug in a pandemic with Immunomedics

Reading now: 202
www.pharmaceutical-technology.com

New Jersey-based Immunomedics focuses on developing novel antibody drug conjugates (ADCs) for hard-to-treat cancers. At the end of April, its first ADC, Trodelvy (sacituzumab govitecan), received US Food and Drug Administration (FDA) accelerated approval in heavily pre-treated metastatic triple negative breast cancer (TNBC).

People in this patient group have essentially experienced disease progression despite being treated with multiple available chemotherapy regimens, creating a significant unmet need in this type of breast cancer, which disproportionately affects younger people and ethnic minorities.

Trodelvy targets Trop-2, a glycoprotein highly expressed on the surface of TNBC cells. It is the first therapy directed at this target in

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA